The Skin, a Novel Niche for Recirculating B Cells

Skye A. Geherin, Sarah R. Fintushel, Michael H. Lee, R. Paul Wilson, Reema T. Patel, Carsten Alt, Alan J. Young, John B. Hay and Gudrun F. Debes

*J Immunol* 2012; 188:6027-6035; Prepublished online 4 May 2012;
doi: 10.4049/jimmunol.1102639
http://www.jimmunol.org/content/188/12/6027

References

This article cites 47 articles, 20 of which you can access for free at:
http://www.jimmunol.org/content/188/12/6027.full#ref-list-1

Subscription

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

*The Journal of Immunology* is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
The Skin, a Novel Niche for Recirculating B Cells

Skye A. Geherin,* Sarah R. Fintushel,* Michael H. Lee,* R. Paul Wilson,* Reema T. Patel,† Carsten Alt,‡,1 Alan J. Young,‡ John B. Hay,§ and Gudrun F. Debes*

B cells infiltrate the skin in many chronic inflammatory diseases caused by autoimmunity or infection. Despite potential contribution to disease, skin-associated B cells remain poorly characterized. Using an ovine model of granulomatous skin inflammation, we demonstrate that B cells increase in the skin and skin-draining afferent lymph during inflammation. Surprisingly, skin B cells are a heterogeneous population that is distinct from lymph node B cells, with more large lymphocytes as well as B-1–like B cells that coexpress high levels of IgM and CD11b. Skin B cells have increased MHC class II, CD1, and CD80/86 expression compared with lymph node B cells, suggesting that they are well-suited for T cell activation at the site of inflammation. Furthermore, we show that skin accumulation of B cells and Ab-secreting cells during inflammation increases local Ab titers, which could augment host defense and autoimmunity. Although skin B cells express typical skin-homing receptors, such as E-selectin ligand and α-4 and β-1 integrins, they are unresponsive to ligands for chemokine receptors associated with T cell homing into skin. Instead, skin B cells migrate toward the cutaneously expressed CCR6 ligand CCL20. Our data support a model in which B cells use CCR6-CCL20 to recirculate through the skin, fulfilling a novel role in skin immunity and inflammation. The Journal of Immunology, 2012, 188: 6027–6035.

The skin is a barrier organ that protects the body from external threats and, thus, harbors many resident leukocytes, including macrophages, dendritic cells, and T cells. During inflammation, these and additional leukocyte subsets are recruited into the skin (1). Although B cells are found in the afferent lymph draining uninfamed skin of both sheep and humans (2, 3), the widely accepted view is that B cells do not enter the skin during homeostasis (4). In contrast, B cells accumulate in the dermis during infection and autoimmunity (5–7), and B cell malignancies can manifest as cutaneous lymphomas. However, despite their association with a wide array of skin pathologies, the phenotypic and functional attributes of skin B cells remain unknown.

B cells can be divided into two lineages: B-1 and B-2 B cells. B-2 B cells include the conventional mature B cell subsets: marginal zone (MZ) and follicular B cells. In contrast, B-1 B cells are an innate-like subset that resides in the peritoneal and pleural cavities and responds to T-independent Ags, bridging innate and adaptive immune responses (8, 9). Although their primary residence is within the coelomic cavities, B-1 B cells are capable of exiting the body cavities in response to infection (10, 11); however, they have not been described to enter the skin.

Lymphocyte recirculation is required for immunosurveillance, host defense, and site-specific immunity. There are two general pathways of lymphocyte recirculation: lymphocytes may arrive at lymph nodes from either blood or extralymphoid tissues (reviewed in Ref. 12). Primarily, blood-borne lymphocytes enter lymph nodes through high endothelial venules. Alternatively, lymphocytes recirculate through extralymphoid tissues, such as skin; exit these tissues by migrating into the afferent lymph to enter the draining lymph node; and then return to the blood stream in the efferent lymph via the thoracic duct. Although two distinct blood-borne B cell subsets differentially recirculate through lymph node or spleen (13), and IgA+B cells preferentially recirculate through mucosal sites (14), little is known about B cell recirculation through nonmucosal extralymphoid tissues. To home to the skin, CD4 T cells rely on the coordinated expression of E-selectin and α-4 and β-1 integrins and use the chemokine receptors CCR4, CCR8, and/or CCR10 (reviewed in Refs. 15–17). In contrast, the molecules involved in B cell migration to the skin remain uncharacterized.

To investigate B cells in the skin, we used a model of lymph cannulation (18) to show that B cells not only traffic through, but are also present in, both uninfamed and chronically inflamed skin. We demonstrate that skin B cells are a heterogeneous population consisting of small and large lymphocytes, with a subset exhibiting a B-1–like phenotype. In addition, skin B cells are well equipped for Ag presentation to T cells in situ, and Ab-secreting cells (ASCs), the effector stage of B cells, accumulate in the chronically inflamed skin, leading to increased local Ab titers. Although skin B cells express α-4 and β-1 integrins and E-selectin ligands, unlike skin T cells, they do not respond to ligands for chemokine receptors associated with T cell homing into skin. Instead, skin B cells are responsive to the cutaneously expressed CCR6 ligand CCL20. These data suggest that skin B cells are key to cutaneous immunity and inflammation and that they use CCR6-CCL20 to home to the skin.

Materials and Methods

Animals, lymph cannulation, and induction of skin inflammation

Intact female or wethers of mixed breed sheep, 5–10 mo of age, were purchased from 3D Livestock (Woodland, CA), the University of Cal-

Received for publication September 13, 2011. Accepted for publication April 11, 2012.

This work was supported by National Institutes of Health Grants AR056730 and P30-AR057217-03 (to G.F.D.), T32AI007532 (to S.A.G.), and 5T32AR7442-25 (to R.P.W.).

Address correspondence and reprint requests to Dr. Gudrun F. Debes, Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104; Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, CA 94305; Center for Infectious Disease Research and Vaccinology, South Dakota State University, Brookings, SD 57007; and Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, Ontario M5S 1A8, Canada

Current address: Stanford Research Institute International, Biosciences Division, Menlo Park, CA.

Copyright © 2012 by The American Association of Immunologists, Inc. 0022-1767/12/$16.00
Skin B cells shown by staining in 30 mM EDTA buffer, which inhibits the Ca\(^{2+}\)-dependent anti-human IgG (Jackson ImmunoResearch). Specificity of the binding was according to appropriate isotype-control staining. Using FACSDiva or CellQuest software (BD Biosciences), respectively, and isolation process. Samples were acquired on a BD LSRII or FACSCalibur Staining of digested skin was performed in parallel with that of digested and trypsin, or Alexa Fluor 405-conjugated streptavidin (Invitrogen), or PerCP-Cy5.5- (BD Biosciences), Pacific Orange- (Invitrogen), and Cy5- (BD Biosciences). Staining with the recombinant mouse E-selectin human IgG chimeric protein (R&D Systems) was tested by assessing binding capacity to the murine anti-sheep Abs were used: CD1 (20.27; Serotec), CD4 (44.38; Serotec), CD8 (38.65; Serotec), CD45 (1.11.32; Serotec), CD11b (12-5-4; 28), and CD11c (17-196; 17). Some mAbs were directly labeled prior to staining using Zenon labeling kits, according to the manufacturer's instructions (Invitrogen). B7.1/B7.2 expression was detected by CTLA4-Ig binding (human chimeric protein; ID Labs). E-selectin ligand expression was tested by assessing binding capacity to a recombinant mouse E-selectin human IgG chimeric protein (R&D Systems) in HBSS containing Ca\(^{2+}\) and Mg\(^{2+}\), followed by biotinylated F(ab\(^{9}\)) donkey anti-human IgG (H+L) (Jackson ImmunoResearch) on the same plate was used to quantify Ab titers.

Chemotaxis assay

For ELISAs, Immulon 4 HBX 96-well plates (Nunc) were coated overnight at 4\(^\circ\)C with 1 \(\mu\)g/ml rabbit anti-ovine IgG (H+L+) (Invitrogen), blocked with heat-inactivated rabbit serum (Life Technologies), and washed with PBS-Tween (PBS containing 0.05% Tween-20). Sterile-filtered blood and lymph plasma samples were diluted with PBS, added to the plate, and incubated for 2 h at 37\(^\circ\)C. Plates were washed with PBS-Tween and incubated for 1 h at 37\(^\circ\)C with 0.2 \(\mu\)g/ml rabbit anti-ovine IgG (H+L+) HRP conjugate (Invitrogen) diluted in PBS containing 0.1% heat-inactivated rabbit serum and 0.05% Tween-20. Plates were washed with PBS-Tween, developed for 5 min using TMB Single Solution (Invitrogen), quenched with 1 M HCl, and read immediately at OD490 using an EMax Endpoint ELISA microplate reader (Molecular Devices). A standard curve derived from whole-ovine IgG (Jackson ImmunoResearch) on the same plate was used.

Statistical analysis

All statistical analyses were conducted using GraphPad Prism software. Unless otherwise indicated, all values are reported as mean \(\pm\) SEM, and statistical significance was determined by the nonparametric Mann–Whitney \(U\) test. For paired analysis, if indicated, the Wilcoxon test was used. The values \(p < 0.05\) were considered statistically significant.

Results

**B cells reside in and recirculate through uninflamed skin**

B cells contribute to many skin diseases, but their role in cutaneous immunity is not well characterized. In contrast to the notion that B cells are generally absent from the uninflamed dermis (3, 4), we consistently detected a population of B cells in the skin of sheep.
Lymphocytes from uninflamed skin, uninflamed skin-draining afferent lymph, and peripheral blood from adult sheep were analyzed. We used an established model of granulomatous skin inflammation, in which inflammation is induced by s.c. injection of CFA (21, 22). Draining lymph vessels were surgically cannulated 3-4 wk later when the typical skin granulomas had formed at the injection sites. As previously shown for total lymphocytes and T cells (21), chronic inflammation also boosted the absolute numbers of B cells exiting the skin (Fig. 2A). Importantly, B cells were the only lymphocyte subsets that showed a consistent relative increase in lymph draining chronically inflamed skin relative to uninflamed (control) skin in all animals (p = 0.0078, Fig. 2B; one example staining shown in Fig. 2C). The percentage of all other lymph-borne lymphocyte subsets (CD4, CD8, and γδ T cells) was not consistently elevated, unchanged, or decreased (Fig. 2B). The data demonstrate that chronic inflammation particularly enhances B cell traffic through the skin.

**B cells accumulate in chronically inflamed skin**

Having found an increase in lymph-borne B cells draining chronically inflamed skin, we isolated lymphocytes from 3-wk-old skin granulomas. We observed that the percentage of B cells was significantly higher in the chronically inflamed skin compared with uninflamed skin (38.3 ± 2.2% versus 5.6 ± 1.1%; p = 0.0079) (Fig. 3A). We also detected B cells by immunofluorescent staining of frozen skin section in both uninflamed and granulomatous skin (Fig. 3B–F). Although only very few IgM+ B cells were visible in the deep dermis of the uninflamed skin (Fig. 3B, 3C), the dermal and s.c. granuloma harbored numerous IgM+ B cells that were dispersed throughout the tissue (Fig. 3D, 3E) or clustered in some areas of the granuloma (Fig. 3F). Thus, B cells are a major constituent of the lymphocytic infiltrate of chronically inflamed skin, suggesting a contribution of B cells to the inflammatory process.

**Skin B cells express high levels of costimulatory molecules and MHCII**

B cell traffic through and residence in uninflamed and inflamed skin raised the possibility that skin B cells may participate in local immune responses by interacting with colocalizing skin T cells. To explore whether skin B cells are equipped for efficient T cell activation, we examined Ag-presenting and costimulatory molecule expression on skin B cells. CD1 is a key Ag-presenting and regulatory molecule related to MHCII that presents lipid molecules to CD1-restricted T cells, such as NKT cells and some γδ T cells, both of which are known to play important roles in the immunosurveillance and immunoregulation of the skin (33, 34). Skin B cells from granuloma-draining lymph (32 ± 6.7%), skin granuloma (42.8 ± 9.5%), and blood (59.7 ± 7.4%) were enriched in the expression of CD1 compared with B cells from control (uninflamed) skin lymph nodes (Fig. 4A). CD1 expression on skin and skin-draining B cells implies that they may interact with skin NKT or γδ T cells, generating an effective cutaneous immune response.

Compared with B cells from a control (uninflamed) lymph node, B cells from uninflamed skin displayed modestly higher expression of CD1 (CD1gd) (Fig. 4B). A more striking difference was observed for B7.1/B7.2 expression (determined by CTLA4-Ig binding). B cells from uninflamed and granulomatous skin, and even more so from skin-draining lymph, expressed higher levels of B7.1/B7.2 than did lymph node B cells (Fig. 4B). Taken together, these data suggest that skin B cells are well equipped for Ag presentation to both canonical and CD1-restricted T cells.

**“Innate-like” B cells reside in and recirculate through uninflamed and inflamed skin**

The phenotype of skin-associated B cells could give insight into the capacity to modulate cutaneous immune responses. IgMhi ex-
expression marks more innate-like B cells, such as MZ and B1 cells, capable of mounting efficient T-independent immune responses. Interestingly, in both the uninflamed (9.3 ± 1.5%; \( p < 0.0001 \)) and granuloma (7.9 ± 1.9%; \( p = 0.0006 \)) skin-draining lymph, we detected a significantly higher proportion of IgMhi B cells compared with skin lymph node B cells, which contained only a negligible population of IgMhi B cells (0.91 ± 0.21%, Fig. 5A, 5B), consistent with the fact that lymph node B cells are largely (IgMlo) follicular B cells. Furthermore, we found significantly more IgMhi B cells in both uninflamed (\( p = 0.002 \)) and granuloma-draining (\( p = 0.0295 \)) afferent lymph than in efferent lymph (1.46 ± 0.41%, Fig. 5A). Sheep blood contains high numbers of IgMhi B-1–like cells (35) and, as expected, we detected a large population of B cells in the blood expressing high levels of IgM (25.33 ± 4.0%, Fig. 5A, 5B). Data suggest that MZ B cells recirculate in humans (36), and MZ B cells are characterized by high expression of CD1 (8). Based on the lower expression of CD1 and that of other MZ B cell markers, such as CD21 and CD9, on skin B cells relative to splenic MZ B cells, we concluded that IgMhi and/or

![FIGURE 2.](image)

**FIGURE 2.** B cell traffic increases in chronic skin inflammation. Chronic cutaneous inflammation was induced by s.c. injection of CFA into sheep flanks. Ovine lymph was collected after catheterization of draining afferent lymphatics of uninflamed (control) or chronically inflamed (3–5 wk after induction of inflammation) skin. (A) Numbers of cells collected from skin-draining afferent lymphatics over time (cell output) were determined for CD4, CD8, and \( \gamma \delta \) T cells and B cells. Data represent the mean ± SEM of multiple time points analyzed for cell output from control (uninflamed) and granulomatous skin. One representative animal of at least four individually analyzed animals is shown. (B) The percentage of lymph-borne CD4, CD8, and \( \gamma \delta \) T cells and B cells draining control and granulomatous skin showing all individually analyzed animals. Connected lines indicate individual animals. (C) Flow cytometric analysis of CD4 and B cells on gated lymphocytes. Numbers indicate the percentage of positive cells in the specified gates. One example staining of at least eight individually analyzed sheep is shown.

![FIGURE 3.](image)

**FIGURE 3.** B cells accumulate in chronically inflamed skin. Healthy control skin and CFA-induced skin granulomas were analyzed 3–5 wk post-induction of inflammation. (A) The percentage of (pan-B cell marker) 2-104–reactive B cells among total lymphocytes isolated from uninflamed and granulomatous skin was determined by flow cytometry for all animals (\( n = 5 \)). (B–F) Immunofluorescence staining of IgM (FITC, green) and DAPI (blue) on 6 μm-thick frozen sections of uninflamed (B, C) or granulomatous (D–F) skin. One representative staining of at least four animals is shown.

![FIGURE 4.](image)

**FIGURE 4.** Skin B cells are well suited for Ag presentation. Lymphocytes from skin granuloma and control skin, skin-draining afferent lymph, and peripheral blood were isolated from sheep. (A) Flow cytometric analysis of CD1 and isotype-control staining on gated B cells (pan-B cell marker 2-104*, MHCII+ lymphocytes) from skin granuloma-draining afferent lymph and blood. Numbers indicate the percentage of positive B cells. (B) Flow cytometric analysis of MHCII expression and CTLA4-Ig binding (B7.1/B7.2 expression) on B cells isolated from lymph node and skin granuloma, control skin, and skin-draining lymph. One representative animal of four (CD1), seven (MHCII), or six (CTLA4-Ig) individually analyzed animals is shown.
CD1+ B cells in the granuloma and granuloma lymph are not MZ B cells (data not shown). Because B-1 cells express CD1 (37), we wondered whether skin-associated B cells belong to this subset. In sheep, CD11b is a marker of B-1–like cells (35); as such, we compared CD11b expression on the skin B cell populations. IgM\(\text{hi}\)-expressing B cells in uninflamed and granulomatous skin and skin-draining lymph, as well as blood, expressed high levels of CD11b relative to total lymph node (follicular) B cells (Fig. 5C). Thus, skin-associated IgM\(\text{hi}\) B cells are of B-1–like phenotype, constitutively traffic through skin, and leave via the afferent lymph. Because ovine B-1–like cells often express CD11c (35), we determined CD11c expression by skin B cells and found that CD11c was expressed at higher frequencies than was CD11b in B cells traveling in skin-draining lymph (Fig. 5D). The microscopic analysis of FACS-sorted and Pappenheim-stained B cells from skin-draining lymph revealed that the double-negative cells consisted of mature lymphocyte ∼10 \(\mu\)m in diameter with a condensed chromatin and scant basophilic cytoplasm (Fig. 5E). In contrast, the slightly larger (∼12–13 \(\mu\)m-diameter) CD11b\(^-/\text{CD11c}^+\) or CD11b\(^+/\text{CD11c}^+\) lymphoid cells exhibited a more open chromatin and deeply basophilic cytoplasm that occasionally contains a fine paranuclear Golgi clearing (Fig. 5E). Analysis of cell diameters confirmed that CD11b\(^-/\text{CD11c}^+\) (12.08 ± 0.21 \(\mu\)m) and CD11b\(^+/\text{CD11c}^+\) (11.92 ± 0.48 \(\mu\)m) B cells were significantly larger than were CD11b\(^-/\text{CD11c}^+\) B cells (10.06 ± 0.40 \(\mu\)m; \(p < 0.0001\)) (Fig. 5F). The cytomorphology suggests that CD11b\(^-\) or CD11c\(^+\) cells are more activated lymphoid cells in contrast to the more quiescent morphology of the dual-negative cells.

**FIGURE 5.** Larger B cells and B-1–like B cells recirculate through the skin. Lymphocytes from skin-draining afferent lymph, control skin-draining lymph node, blood, and skin were isolated from sheep. (A) The relative distribution of IgM\(\text{hi}\), IgM\(\text{lo}\), and IgM\(\text{neg}\) among B cells (pan-B cell marker 2-104+, MHCII+ lymphocytes) from different tissues based on flow cytometry. Data represent the mean ± SEM of four to eight individually analyzed animals per tissue. (B) One representative staining of IgM expression on B cells from control (uninflamed) skin- and skin granuloma-draining lymph, control skin lymph node, and blood is shown. (C) Flow cytometric analysis of CD11b expression on skin, lymph, and blood IgM\(\text{hi}\) B cells compared with total lymph node B cells (pan-B cell marker 2-104+, MHCII+ lymphocytes). One representative animal of at least three (control skin) or four (all other tissues) individually analyzed animals is shown. (D) Flow cytometric analysis of CD11b and CD11c coexpression on blood and afferent lymph B cells. (E) B cells (live, lymphocytes, MHCII+, pan-B cell marker+) were FACS sorted according to specified CD11b and CD11c expression, cytospun, and stained with Pappenheim stain for cytological evaluation. (F) Quantification of cellular diameters from (E). One representative of a minimum of three individually analyzed lymph samples is shown in (D–F). ***\(p < 0.0001\).

**FIGURE 6.** Ab titers and ASCs increase locally during chronic skin inflammation. (A) ELISA of total Ig Ab titers in plasma from blood and afferent lymph draining control skin or chronically inflamed skin (granuloma). (B) ELISPOT assay analyzing total Ig-secreting cells in blood, uninflamed control, or granulomatous skin of the same animal. In (A) and (B), individual animals are identified by unique symbols; bars represent the mean ± SEM. (C) Developed ELISPOT wells analyzing 2 \(\times\) 10^5 and 1 \(\times\) 10^4 cells/well from uninflamed control and granulomatous skin, respectively. One representative animal of three is shown. *\(p < 0.05\).
correlated with Ab production in the tissue, we enumerated ASCs by ELISPOT assays and found that ASCs also accumulated (~400-fold on average) in the chronically inflamed skin relative to control skin of the same animals (Fig. 6B, 6C). Ab titers in the draining lymph did not increase to the same extent as did the ASCs in the tissue. This is not unexpected, because the cannulated lymphatics drain a larger site than just the granuloma region, causing the Ab titers to be a diluted average of the entire drainage site.

Although chronic inflammation is generally not associated with increased vascular leakage, we excluded that the increased Ab titers were not simply a result of increased blood vascular permeability. We analyzed Ig levels in skin-draining lymph plasma during acute CFA-induced inflammation (<24 h), which is characterized by drastic blood vascular leakage and edema, and found that Ab titers did not increase (data not shown). This verifies that poor vessel integrity was not responsible for the increased Ig titers in the granuloma lymph. Based on these data, we conclude that B cell accumulation in the chronically inflamed skin leads to increased localized Ab production and titers that are potentially important in the defense against skin pathogens but that could also be harmful during autoimmunity.

**CD21 and L-selectin expression on skin-associated B cells**

Expression of CD21 and L-selectin marks a pool of B cells that preferentially recirculates between blood and lymph nodes, leading to their enrichment in efferent lymph (13). In contrast, the lack of CD21 and L-selectin is associated with preferential migration to the spleen, a low ability to leave the blood, and an ensuing enrichment in the blood (13). We compared B cells in the afferent lymph draining the skin with these B cell pools and found that the majority of B cells in afferent lymph were positive for CD21 (55.72 ± 6.94%) and L-selectin (70.64 ± 6.67%), as was a smaller population of B cells in the blood (CD21, 37.54 ± 5.31%; L-selectin, 54.38 ± 8.92%) (Fig. 7). In contrast, only a small population of B cells isolated from the skin expressed either CD21 (16.5 ± 3.17%) or L-selectin (13.35 ± 3.34%) (Fig. 7). Thus, CD21 and L-selectin expression does not clearly delineate skin B cells into known recirculating and nonrecirculating B cell pools.

![FIGURE 7.](http://www.jimmunol.org/)

**Skin B cells use a unique repertoire of trafficking receptors**

We next examined adhesion molecule expression that denotes skin-homing versus gut-homing lymphocytes. As previously shown, and specific to skin-tropic T cells (24), CD4 T cells in skin-draining lymph expressed high levels of both α-4 and β-1 integrins, as well as low levels of β-7 integrin (Fig. 8A, top panels). As expected (24), CD4 T cells in the blood contained a population of cells that expressed high levels of α-4 and β-7, consistent with the presence of gut-homing T cells (Fig. 8A). Unexpectedly, lymph-borne B cells showed equal or lower expression of α-4 and β-1 integrins, but higher levels of β-7 integrin, relative to coisolated skin-draining CD4 T cells (Fig. 8A). CD4 T cells from the blood and skin lymph had distinct integrin-expression patterns, which are consistent with known phenotypes of skin (α4β1 hi, α4β7 lo) versus...
gut (αβ1(2), αβ2(3)) homing. However, B cells from blood and lymph had near-identical expression patterns of the integrins examined (Fig. 8A). To address whether the integrin-expression pattern for B cells is homogenous throughout the body, we examined B cells traveling in the mesenteric efferent lymph (Fig. 8B). We found that mesenteric lymph B cells, but not blood or skin lymph B cells, were uniformly high in the expression of αβ integrin (Fig. 8A, 8B), which, when paired with α-4 integrin, is required for gut homing. Thus, B cells at different anatomic sites exhibit distinct integrin-expression patterns, such as known gut-versus skin-homing phenotypes. Furthermore, although approximately half (57.1 ± 9.5%) of the skin-draining CD4 T cells expressed E-selectin ligand, B cell expression of this skin-homing molecule was enriched compared with blood B cells but significantly lower relative to skin T cells (14.8 ± 4.9%, p = 0.02, paired t test, Fig. 8C).

The chemokine receptor requirements for entry into the skin have been well studied for some leukocyte subsets. For T cells, CCR4, CCR8, and CCR10 are important in mediating entry into skin in mice and humans (15–17). Data imply that CCR6 mediates the migration of Langerhans cell precursors into skin (38, 39). Therefore, we tested whether skin-associated B cells migrate in response to ligands for these skin-associated chemokine receptors in an in vitro chemotaxis assay. In contrast to coisolated CD4 T cells, B cells traveling in skin-draining lymph were not responsive to CCL17, CCL1, and CCL28, ligands for CCR4, CCR8, and CCR10, respectively (Fig. 8D). Surprisingly, skin B cells migrated well in response to the CCR6 ligand CCL20. Taken together, the data suggest that B cells use CCR6 or alternative chemoattractant receptors for their recirculation through skin.

Discussion

B cells are capable of many effector functions beyond Ab production; however, their role in most extralymphoid tissues has yet to be defined. Recent studies show that B cells accumulate in the inflamed skin in a variety of diseases, including cancer, autoimmunity, and infection (6, 7, 40). To shed light on the role of skin-associated B cells, we examined the migration and phenotype of cutaneous B cells.

It is often assumed that B cells do not reside in or recirculate through the skin in the absence of inflammation (4). In contrast to that assumption, we found that B cells are present in both uninflamed skin-draining afferent lymph and the uninflamed flank skin itself (Fig. 1A); thus, B cells continuously traffic through the skin and are a steady-state population of this organ. Studies by other investigators showed that B cells travel in the afferent lymph draining from uninflamed human skin (3), suggesting that B cells are characteristic of mammalian skin.

Our study further revealed that, during chronic inflammation, skin-draining B cells exhibit the most consistent and greatest relative increase of all lymphocyte subsets studied (B cells and CD4, CD8, and γδ T cells) (Fig. 2). Importantly, B cells dramatically accumulated in the inflamed skin to constitute nearly half of all lymphocytes in the granuloma (Fig. 3). Large numbers of B cells are often found in Mycobacterium tuberculosis granulomas of the lung, in which they play a protective role by aiding in the recruitment of other immune cells (41). B cells may fulfill a similar role in chronic skin inflammation. We found increased expression of Ag-presenting and costimulatory molecules on skin-associated B cells relative to lymph node B cells (Fig. 4). Consequently, B cells in afferent lymph may migrate into lymph nodes to activate naïve T cells, whereas B cells in the granuloma may be capable of stimulating effector/memory T cells at the site of inflammation, thereby boosting the inflammatory response. In that regard, B cell Ag presentation could be of critical importance, because B cells are able to present their cognate Ag efficiently at very low concentrations relative to other APCs (42).

B cells are key players in many autoimmune diseases, even in those that were primarily considered T cell mediated, such as multiple sclerosis (6, 43). Furthermore, B cell depletion in humans revealed a role for B cells in cutaneous disorders, including bullous skin diseases (6) and atopic eczema, a condition not typically associated with autoantibody (44). Moreover, in some systemic autoimmune disorders with cutaneous manifestations, such as systemic lupus erythematosus, the clinical improvement following B cell depletion does not always correlate with a decline in autoantibody titers, suggesting that B cell functions other than Ab production (i.e., Ag presentation and cytokine production) are critical in cutaneous immune responses (6).

B-1 cells are typically located within the peritoneal and pleural cavities, sites of constant microbial exposure. By producing natural Ab and rapidly mounting T-independent immune responses that result in the production of broadly specific, cross-reactive IgM, B-1 cells are important early in the immune response against pathogens (8). Our analysis revealed that a subset of skin and skin-draining lymph B cells is IgM(+)CD11b(+) (Fig. 5) and, thus, resembles B-1-like cells that were previously described in sheep blood (35). Ninety percent of efferent lymph lymphocytes are blood derived, and only 10% originate from the afferent lymph (12, 45). Therefore, the appearance of B-1-like B cells in skin, skin-draining lymph, and blood, in combination with their relative absence in lymph nodes and efferent lymph (Fig. 5), suggests that a population of B-1-like B cells migrates between blood and skin and egresses via the afferent lymph and that only few B-1-like B cells recirculate between blood and lymph nodes.

We propose that B-1-like cells recirculate through skin as a first line of defense against pathogens that invade via the epidermis. In line with the notion of a skin-surveying B-1-like B cell, B-1 cells were shown to recirculate between the body cavities and blood (46) and to migrate into the lung and draining lymph nodes during pulmonary infection (10, 47). Additionally, B-1 cells migrate from the peritoneal cavity to the skin-draining lymph nodes during the course of cutaneous contact hypersensitivity (48). Our study extends these findings by showing that B-1-like cells recirculate through the skin itself; thus, they are well positioned to participate in protec tive, as well as harmful, cutaneous immune responses.

Abs secreted by differentiated B cells, including B-1 cells, are key effector molecules in the defense against invading pathogens; however, they can also be pathogenic in autoimmune and allergy. Total Ig titers in skin-draining lymph were well below that of the blood, suggesting that Ab does not fully penetrate and/or saturate the skin. This finding could be of great consequence to the many disease treatments that use depleting Ab if i.v. administration does not effectively reach the skin. We found that B cell and ASC accumulation in the skin during chronic inflammation leads to increased localized Ig titer (Fig. 6A). This localized Ab production in the skin likely represents a mechanism by which the body clears or contains an ongoing skin infection and ensures protection against reinfection. Although an accumulation of pathogen-specific ASCs and B cells would be beneficial, the recruitment of autoreactive B cells to the site of inflammation with subsequent localized Ab production has the potential to exacerbate inflammation in autoimmune diseases that affect the skin, such as cutaneous lupus erythematosus or pemphigus.

Young et al. (13) found that efferent lymph B cells segregate into recirculating and nonrecirculating cell pools. The lymph node recirculating pool was marked by expression of CD21 and L-selectin. Conversely, CD21 and L-selectin double-negative
B cells were excluded from lymph node recirculation and preferentially migrated into the spleen. Consistent with the concept that leukocytes in the afferent lymph are migrating to the lymph node, we find that slightly fewer afferent lymph B cells costain for both of these markers (Fig. 7) than what was shown for efferent lymph B cells (13). It is conceivable that the CD21−L-selectin− afferent lymph B cells do not migrate from the blood to lymph nodes via high endothelial venules and instead enter the lymph node by way of (skin) tissue and afferent lymph. Surprisingly, a lower percentage of B cells isolated from the uninfamed skin, but not the granuloma, were positive for both CD21 and L-selectin. The difference in CD21 and L-selectin expression between B cells residing in skin and B cells exiting the skin suggests that they represent two different populations: one that is sessile in and one that recirculates through skin. Alternatively, these markers could be upregulated once a B cell exits from skin. This difference is only observed in uninfamed skin, implying that the lack of CD21 and L-selectin denotes a skin-resident population that is diluted as B cells traffic to and accumulate in the chronically inflamed skin.

Although the mechanisms by which T cells migrate into skin are well characterized and critical to cutaneous inflammation and immunosurveillance (16), little is known about B cell migration into skin. In this study, we observed that B cells in the skin-draining lymph expressed high levels of α4 and β1 integrins, and a smaller subset bound E-selectin (Fig. 8). Thus, skin B cells are well equipped with adhesion molecules typically associated with T cell homing to the skin. Importantly, CD4 T cells draining the skin were responsive to chemokine ligands for CCR4, CCR10, and CCR8 (Fig. 8D), chemokine receptors key to the recruitment of T cells into skin in mice and humans (49). Ligands for CCR4, CCR10, and CCR8 were also able to attract skin-draining CD4 T cells in the sheep, implying that the mechanism of skin homing via these receptors is evolutionarily conserved. However, ciliated ovine skin B cells were unresponsive to ligands for these receptors (Fig. 8), suggesting that B cells use alternative chemokine receptors to migrate into skin.

The CCR6 ligand CCL20 is constitutively expressed in the epidermis and by dermal endothelial cells and presumably mediates the recruitment of Langerhans cell precursors into skin (38). Although most blood-borne B cells express surface CCR6, they lack responsiveness to CCL20 but acquire it upon BCR stimulation (50). Our study shows that skin-draining B cells are spontaneously responsive to CCL20; thus, the CCR6-CCL20 axis is a likely candidate for mediating B cell localization to skin. Rituximab, an Ab to human CD20, depletes circulating B cells to effectively treat B cell lymphomas and autoimmune disorders, including skin diseases (6). However, the efficacy of B cell depletion in many extralymphoid sites, including the skin, remains unknown. As an alternative approach, targeting specific trafficking molecules, such as CCR6, to restrict B cell entry into effector sites could reduce disease pathology while not affecting general B cell function.

In conclusion, our data show that innate-like and conventional B cells with the potential to activate T cells or produce Ab reside in and/or continuously recirculate through healthy and inflamed skin. Thus, our study reveals a so-far unappreciated role for skin B cells as potential regulators of cutaneous immunity and inflammation.

Acknowledgments

We thank the Flow Cytometry and Cell Sorting Resource Laboratory for technical advice and cell sorting, University Laboratory Animal Resources, large animal surgical staff for excellent technical assistance, and Dr. Anthony Carty for veterinary support. We are indebted to Mike Cancro, Nina Luning Prak, and Dave Allman for helpful discussions; Irene Chernova and Martin Naradikian for after-hours cell sorting; and Eugene Butler for support of early experiments.

Disclosures

The authors have no financial conflicts of interest.

References


